Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

BACKGROUND: Alzheimer’s disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) followed by y-secretase. Verubecestat is an oral BACE-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Egan, Michael F., Kost, James, Tariot, Pierre N., Aisen, Paul S., Cummings, Jeffrey L., Vellas, Bruno, Sur, Cyrille, Mukai, Yuki, Voss, Tiffini, Furtek, Christine, Mahoney, Erin, Mozley, Lyn Harper, Vandenberghe, Rik, Mo, Yi, Michelson, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6776074/
https://ncbi.nlm.nih.gov/pubmed/29719179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1706441
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados